With the wrong architecture in place, AI algorithms can nudge biopharmaceutical developers toward unpredicted and misaligned ...

Biotech is the most honest leadership environment in the world. Science does not soften bad news. Markets do not wait for leaders to feel ready. And the pressure does not lift between a failed trial, ...

In the pharmaceutical industry, where innovation cycles span decades and billions of dollars hinge on patent protection, the relationship between a company and its external intellectual property ...

During the anniversary celebration, guests could see highlights from Biogen's history in RTP on a special wall. North Carolina’s life sciences sector surged in 2025, drawing nearly $3.8 billion in new ...

The Port of Wilmington is 284 acres with an inside harbor channel depth of 42 feet M.L.L.W. North Carolina’s rise as a global life sciences powerhouse is rooted in decades of supply‑chain strength.

Charlotte’s life sciences landscape entered a new era in 2025, with long‑planned initiatives finally taking shape and redefining the region’s national profile. The opening of The Pearl innovation ...

On this week's episode of the Business of Biotech, Rob Abbott, CEO of ISPOR, explains how startup and early-stage clinical drug development companies benefit from conducting health economics and ...

On this week's episode of the Business of Biotech we speak with Rahul Aras, Ph.D., President and CEO at Iterion Therapeutics, about capital efficient drug development in oncology and progressing a ...

On this week's episode of the Business of Biotech, we're speaking with Thomas von Erlach, Ph.D., Cofounder and CEO at Vivtex, a company spun out of the Langer Lab at MIT that's focused on developing ...

Health Canada's Public Release of Clinical Information (PRCI) initiative requires sponsors to anonymize clinical data from drug submissions and medical device applications before it's posted to the ...